In a letter to Eli Lilly, the FDA has warned the pharmaceutical giant that its television advertisement for Strattera “is false or misleading because it inadequately communicates the indication for Strattera and minimizes the risk associated with Strattera.”
The FDA found, that in addition to minimizing the drug’s risks, the ad was misleading in that it suggests a broader indication for the drug as a treatment for ADD (Attention Deficit Disorder) a somewhat similar, but nonetheless medically different condition from ADHD.
The ad clearly depicts behavior which is typically associated with ADD. A voiceover also specifically refers to Strattera as a treatment for adult ADD. Currently, the drug is only approved as a treatment for ADHD. Although Lilly disagrees with the warning, it has already pulled the ad from television.